Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U-DANCE-anti-AML trial of WT1-loaded autologous cord blood-derived dendritic cell vaccination after cord blood transplant
NL-OMON58982Phase 1Suspended
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Dec 2023
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of WT1-loaded CBDC vaccine in acute myeloid leukemia (AML) (3 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Dose-limiting toxicities and One-year WT1-positive AML relapse-free survival. Started Dec 2023; status: suspended.
02
Drugs
WT1-loaded CBDC vaccine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON58982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58982.